Quantitative Proteomics of Strong and Weak Biofilm Formers of Reveals Novel Regulators of Biofilm Formation
Overview
Cell Biology
Molecular Biology
Authors
Affiliations
is a bacterial pathogen associated with both endodontic and systemic infections. The biofilm formation ability of plays a key role in its virulence and drug resistance attributes. The formation of biofilms on implanted medical devices often results in treatment failure. In the present study, we report protein markers associated with the biofilm formation ability of using iTRAQ-based quantitative proteomics approach. In order to elucidate the biofilm-associated protein markers, we investigated the proteome of strong and weak biofilm-forming clinical isolates in comparison with standard American Type Culture Collection (ATCC) control strains. Comparison of strong and weak biofilm-forming clinical isolates with ATCC control strains showed that proteins associated with shikimate kinase pathway and sulfate transport were up-regulated in the strong biofilm former, while proteins associated with secondary metabolites, cofactor biosynthesis, and tetrahydrofolate biosynthesis were down-regulated. In the weak biofilm former, proteins associated with nucleoside and nucleotide biosynthesis were up-regulated, whereas proteins associated with sulfate and sugar transport were down-regulated. Further pathway and gene ontology analyses revealed that the major differences in biofilm formation arise from differences in metabolic activity levels of the strong and weak biofilm formers, with higher levels of metabolic activity observed in the weak biofilm former. The differences in metabolic activity could therefore be a major determinant of the biofilm ability of The new markers identified from this study can be further characterized in order to understand their exact role in biofilm formation ability. This, in turn, can lead to numerous therapeutic benefits in the treatment of this oral and systemic pathogen. The data has been deposited to the ProteomeXchange with identifier PXD006542.
Gallic Acid: A Potent Metabolite Targeting Shikimate Kinase in .
Alturki M, Al Khzem A, Gomaa M, Tawfeeq N, Alhamadah M, Alshehri F Metabolites. 2024; 14(12).
PMID: 39728508 PMC: 11677302. DOI: 10.3390/metabo14120727.
Acosta F, Montero D, Izquierdo M, Galindo-Villegas J Aquaculture. 2024; 532:736004.
PMID: 39175494 PMC: 11338163. DOI: 10.1016/j.aquaculture.2020.736004.
Li H, Li J, Hu J, Chen J, Zhou W Front Cell Infect Microbiol. 2024; 14:1393108.
PMID: 38975327 PMC: 11224960. DOI: 10.3389/fcimb.2024.1393108.
Jiang W, Zhang Y, Yan J, He Z, Chen W Technol Health Care. 2024; 32(S1):371-383.
PMID: 38759062 PMC: 11307051. DOI: 10.3233/THC-248033.
How to study biofilms: technological advancements in clinical biofilm research.
Cleaver L, Garnett J Front Cell Infect Microbiol. 2023; 13:1335389.
PMID: 38156318 PMC: 10753778. DOI: 10.3389/fcimb.2023.1335389.